Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid

Stock News

Sep 24

YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.

On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.

As China's AI medical transformation driver, YIDU TECH has built a "data-algorithm-scenario" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of "medical-pharmaceutical-insurance-patient".

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1120477928"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120477928\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120477928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120477928","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid","media":"Stock News","content":"<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | YIDU TECH (02158) Surges Over 5% After Winning SMR001 Eye Drop Phase III Clinical Research Project Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-24 11:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.</p>\n<p>On the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.</p>\n<p>As China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"南方两倍做多恒科","start_time":0,"source_url":"","article_id":"1120477928","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120477928","pubTimestamp":1758685339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million. On the news front, YIDU TECH announced that its affiliated company Tianjin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07226":"南方两倍做多恒科","HSCEI":"国企指数","BK1189":"医疗保健技术","BK1617":"AI医疗","BK4134":"信息科技咨询与其它服务","02158":"医渡科技","YANG":"三倍做空富时中国ETF-Direxion","BK4614":"Manus概念股","BK1518":"SaaS概念","III":"信息服务"},"translate_title":"港股快讯|医渡科技(02158)大涨超5%中标SMR001滴眼液III期临床研究项目","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02158":1,"07226":1,"HSCEI":1,"III":1,"YANG":1},"content_text":"YIDU TECH (02158) surged over 5%. As of press time, the stock rose 5.39% to HK$6.06, with a turnover of HK$74.9734 million.\nOn the news front, YIDU TECH announced that its affiliated company Tianjin Happy Life Technology Co., Ltd. recently won the bid for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop Phase III clinical research project, with a total project value of approximately RMB 55.82 million.\nAs China's AI medical transformation driver, YIDU TECH has built a \"data-algorithm-scenario\" flywheel closed loop based on its independently developed core algorithm engine YiduCore, achieving high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making to empower the entire industrial chain ecosystem of \"medical-pharmaceutical-insurance-patient\".","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}